Latest Morning Briefing Stories
In an effort to speed up the delivery of COVID-19 test results, the Centers for Medicare and Medicaid Services says it will pay less to labs that take longer than 2 days.
Pfizer CEO Albert Bourla says his company’s mid-October target to apply for FDA emergency use authorization for its COVID-19 vaccine candidate has shifted to mid-November, at the earliest.
Arizona Gov. Doug Ducey, who toured with Education Secretary Betsy DeVos, said families deserve options for learning despite an uptick in cases. More school news is from New York, the District of Columbia, Massachusetts, Indiana and elsewhere.
These patients spent, on average, 4.5 fewer days in intensive care than those with Type A or AB blood. The latter group averaged 13.5 days in the ICU and was more likely to require ventilators.
Remdesivir is the only antiviral drug authorized for treatment of COVID in the U.S., and the results are likely a major blow to scientists hunting for a viable medication.
Whether making it, transporting it or administering it, every step of the COVID vaccination process is rife with complications, Stat reports.
The Centers for Medicare and Medicaid Services approved a waiver request from Georgia to expand its Medicaid program with restrictions that narrow the number of residents who will be eligible.
Up to now, the stimulus stalemate has primarily been between House Democrats and White House negotiators. But the latest $1.8 trillion proposed package, which President Donald Trump says he supports, was nixed Thursday by Senate Majority Leader Mitch McConnell.
President Donald Trump announced his plan ahead of legal and regulatory reviews, which are now bogged down by questions of whether the White House has the authority to outlay billions in Medicare funds. One anonymous administration official tells AP that the odds are 75-25 it won’t happen.
The Trump administration rejected California’s request for disaster-relief funds to help it recover from some of the worst wildfires in the state’s history. It also recently withheld health care funds from 9/11 first responders and stimulus checks from incarcerated people, and has threatened to withhold COVID grants from “anarchist” cities.
COVID-19 played a major role in canceling a second in-person debate between President Donald Trump and former Vice President Joe Biden, while also dominating the stage of the candidates’ alternative town hall events.
The Biden team revealed some specifics about the first known positive tests among campaign staffers Thursday and stressed the protective measures they are taking. And Democratic vice presidential nominee Kamala Harris halted weekend travel plans “out of an abundance of caution.”
With the approval, there are now both a vaccine — Merck’s Ervebo — and a therapeutic to battle Ebola Zaire, one of the deadliest infections known to humankind. The treatment, Inmazeb, is an antibody cocktail made by Regeneron Pharmaceuticals, the same company that is developing a monoclonal antibody treatment for COVID that was given to President Donald Trump this month.
A surge in COVID cases across the United States, as well as a lack of precise information about how the virus spreads indoors, threatens holiday celebrations this year.
Negotiations over an additional coronavirus relief package remain stalled, as both sides are still at odds over issues like employer liability and oversight of aid to states.
EpiVacCorona, described as a “peptide-based shot,” has yet to even begin large-scale trials. Russia announced its first vaccine, Sputnik V, on Aug. 11.
The Centers For Medicare and Medicaid Services is also adding additional telehealth services to coverage.
The rosy picture the Trump administration painted for the public in the early weeks of the coronavirus outbreak contrasts with the more dire closed-door briefings provided by economists to administration officials and Republican donors and passed along to investors, the New York Times reports. In other administration news: Dr. Deborah Birx’s role in undermining WHO and efforts to halt Nevada from using Chinese-made COVID test kits.
The letter is a direct rebuttal to reports this week that Trump administration is pushing the controversial approach. “This is a dangerous fallacy unsupported by scientific evidence,” the letter says. “Uncontrolled transmission in younger people risks significant morbidity and mortality across the whole population.”
Clinicians, pharmacists and hospital information technology staff will be asked to answer questions evaluating the EHR systems’ interoperability, usability, privacy and other factors. In other news, a doctor faces trial after reports that he mistreated patients with unnecessary gynecological surgeries.